NCT06815185 Rehabilitation Counselling for Patients with Interstitial Lung Disease
| NCT ID | NCT06815185 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Condition | Fibrosis, Pulmonary |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2022-12-15 |
| Primary Completion | 2027-07-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2022-12-15 with a primary completion date of 2027-07-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Idiopathic pulmonary fibrosis (IPF) is a rare chronic progressive disease of unknown etiology that affects physical and emotional well-being. It is characterized by irreversible loss of lung function due to fibrosis, which manifests itself with cough, dyspnea, and impaired quality of life. Lung transplantation is limited to a minority of patients and patients receive anti-fibrotic therapy in addition to supportive/palliative treatments. In light of the broad definition of pulmonary rehabilitation, and by virtue of the multidisciplinary nature of the process, the present study aims to observe the effects of the rehabilitation counseling offered to patients who attend the IPF clinic at the Pneumology Operating Unit of the IRCCS Company Bologna University Hospital, as part of the Intercompany PDTA (diagnostic therapeutic care path) for Pulmonary Fibrosis: the Intercompany PDTA for patients suffering from idiopathic pulmonary fibrosis involves a multidisciplinary approach which, also through therapeutic education/counselling, aims among others to "Offer the patient the opportunity to participate in clinical studies to increase knowledge about the disease and/or have access to innovative treatments". Primary objectives 1. Evaluate the effectiveness of the rehabilitation intervention contained in the PDTAI (Intercompany diagnostic therapeutic care path ) 2. Evaluate the improvement in functional capacity and cardiorespiratory endurance. Secondary objectives 3. Evaluate the progress and evolution of the pathology. 4. Evaluate the emotional burden of the caregiver in caring for the individual suffering from IPF 5. Evaluate the improvement in quality of life. 6. Evaluate the change in disability. 7. Evaluate the patient\'s fatigue and its evolution over the course of the disease. Fatigue is associated with dyspnea, impacts daily living activities and quality of life. 8. Evaluate the progress and evolution of dyspnea at rest and in relation to the performance of common daily activities. The study plans to enroll 40 patients newly diagnosed with IPF Inclusion criteria: * adulthood ≥18 years * Obtaining the patient\'s informed consent Exclusion criteria: * diagnosis of cancer in the active phase * Situations of clinical instability, of clinical worsening such as to deem the individual unsuitable for treatment because they are no longer able to go to follow up visits The included patients will receive the therapeutic education brochure from the physiotherapist and will be trained to perform the exercises during hospital visits. The physiotherapist will be able to evaluate and modify the retraining program based on the user\'s response according to the principles based on the individualized rehabilitation project. The direct comparison with the user allows to obtain a functional improvement adapted to the needs and performance of the person but at the same time, according to the principles of empowerment, helps the subject to become aware of their functional limits and address them with a more personalized. The sessions will be planned following the criteria of frequency, intensity, time and type of exercise: Frequency: one meeting/every fifteen days in the first month and one meeting every fifteen days (+/- five days) in the second and third months. Intensity: sixty minutes (with mBorg three dyspnea and minimum peripheral saturation 88%) Time: sixty minutes Type of treatment: exercises from the therapeutic education brochure. Endpoints measures: 1. % of patients participating in the physiotherapy session programme. It is expected that at least 80% of the total enrolled participants will participate in the proposed session cycle. 2. Six Minute Walking Test. This test is validated for multiple pathologies, including idiopathic pulmonary fibrosis. 3. % Survival of IPF patients. 4. Caregiver Strain Index. 5. EuroQoL scale. 6. Barthel Index Dyspnea. 7. Fatigue Assessment Scale. 8. Modified British Medical Research Council.
Eligibility Criteria
Inclusion Criteria: * age\>/= 18 years old; * Obtaining the patient\'s informed consent Exclusion Criteria: * Diagnosis of active cancer * Situations of clinical instability, clinical aggravation such as to consider unsuitable the individual to treatment because he or she is no longer able to go to follow-up visits
Contact & Investigator
Enrica Cavalli, MD
PRINCIPAL INVESTIGATOR
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Frequently Asked Questions
Who can join the NCT06815185 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Fibrosis, Pulmonary. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06815185 currently recruiting?
Yes, NCT06815185 is actively recruiting participants. Contact the research team at enrica.cavalli@aosp.bo.it for enrollment information.
Where is the NCT06815185 trial being conducted?
This trial is being conducted at Bologna, Italy.
Who is sponsoring the NCT06815185 clinical trial?
NCT06815185 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The principal investigator is Enrica Cavalli, MD at IRCCS Azienda Ospedaliero-Universitaria di Bologna. The trial plans to enroll 40 participants.